Dr Daniel Von Hoff MD FACP
DANIEL VON HOFF, MD, FACP
His Leadership Has Led To 3 of 4 Drugs Approved By The FDA For The Treatment of Pancreatic Cancer
Daniel D. Von Hoff, M.D., F.A.C.P. FASCO, FAACR is a Distinguished Professor at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona. He holds the Virginia G. Piper Distinguished Chair for Innovative Cancer Research at HonorHealth Clinical Research Institute and the Margaret Givan Larkin Endowed Chair in Developmental Cancer Therapeutics at Hoag Hospital and Medical Director of Research at McKesson Specialty Health and the Chief Scientific Officer for US Oncology Research specializing in phase I clinical trials. He is also Professor of Medicine at the University of Arizona and at the Mayo Clinic, Scottsdale, AZ and Senior Consultant of Clinical Investigation at the City of Hope.
Dr. Von Hoff’s major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many FDA approved agents we now use routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib, vismodegib, nab-paclitaxel, nal-IRI, pexidartinib and others.
Dr. Von Hoff has published more than 741 papers, 143 book chapters and over 1186 abstracts. Dr. Von Hoff received the 2010 David A.Karnofsky Memorial Award from the American Society of Clinical Oncology for his outstanding contributions to cancer research leading to significant improvement in patient care and most recently the AACR Distinguished Public Service Award in recognition of his extraordinary clinical research career and leadership in establishing the AACR/ASCO Methods in Clinical Cancer Research Workshop to educate and train young clinical investigators.
Dr. Von Hoff was appointed to President Bush’s National Cancer Advisory Board in 2004-2010.
He is the past President of the American Association for Cancer Research (the world’s largest cancer research organization), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEX™ Oncology, Inc. (acquired by Genzyme after Ilex had 2 agents, alemtuzumab and clofarabine approved by the FDA for patients with leukemia).
Read More About Dr. Daniel Hoff
Dr. Daniel Von Hoff Named One of Of ASCO’s 50 Oncology Luminaries
Increased Survival in Pancreatic Cancer With Nab–Paclitaxel Plus Gmecitabine
Dr. D. Von Noff is an international recognized physician scientist
OncLive Presents Giants of Cancer Care
Dr. Von Hoff Has Been Instrumental in the Development of Life Saving Cancer Therapies
Dr. Von Hoff Receives Inaugural AACR Scientific Achievement Award
Abraxanxe and Gemcitabine For Advance Pancreatic Cancer
Dr. Von Hoff Named A “Giant of Cancer Care
Three Drug Combo Shrinks Tumors and Improves Pancreatic Cancer Survivorship
TGEn and HonorHealth Research Institute Clinical Trial Report High Rate of Tumor Shrinkage